Detalhe da pesquisa
1.
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma.
Blood
; 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38728378
2.
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma.
Blood
; 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38728430
3.
GPRC5D-Targeted CAR T Cells for Myeloma.
N Engl J Med
; 387(13): 1196-1206, 2022 09 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36170501
4.
Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta-analysis.
Am J Hematol
; 99(6): 1056-1065, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38488702
5.
Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients.
Haematologica
; 108(11): 3058-3067, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37345467
6.
Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach.
Am J Hematol
; 98(3): 421-431, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36588413
7.
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
Br J Haematol
; 196(1): 105-109, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34396516
8.
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma.
Biol Blood Marrow Transplant
; 26(8): 1394-1401, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32442725
9.
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Biol Blood Marrow Transplant
; 26(10): e247-e255, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32589921
10.
Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.
Br J Haematol
; 189(5): 904-907, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32026474
11.
Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma.
Am J Hematol
; 94(12): 1364-1373, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31571261
12.
Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance.
Biol Blood Marrow Transplant
; 24(4): 871-876, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29288818
13.
Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls.
Haematologica
; 107(1): 284-286, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34474548
14.
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.
Am J Hematol
; 97(7): E276-E280, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35472167
15.
Monoclonal gammopathy-associated pure red cell aplasia.
Br J Haematol
; 173(6): 876-83, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26999424
16.
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2 ) in combination with lenalidomide and dexamethasone.
Am J Hematol
; 96(6): E193-E196, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33661527
17.
Pursuing the curative blueprint for early myeloma.
Blood
; 122(4): 486-90, 2013 Jul 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-23782936
18.
Second malignancies after multiple myeloma: from 1960s to 2010s.
Blood
; 119(12): 2731-7, 2012 Mar 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-22310913
19.
Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease.
Cytokine
; 69(2): 294-7, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25043675
20.
Smoldering multiple myeloma: present position and potential promises.
Eur J Haematol
; 92(1): 1-12, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24112232